Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein Cholesterol
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1561 participants.
Also called NCT03399370
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,561 participants
- Sponsor
- Registry
-
NCT03399370
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT03399370. Randomized; double masking; primary purpose treatment. Start 2017-12-21 (actual); primary completion 2019-09-10 (actual). Results posted on 2020-10-05.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein Cholesterol
- Acronym
- ORION-10
- Condition
- ASCVD
- Condition
- Elevated Cholesterol
- Intervention (Drug)
- Inclisiran Sodium
- Intervention (Drug)
- Placebo
- Lead sponsor
- The Medicines Company
Record details
- Record id
cardio:ct-nct03399370- Content hash
dda531ef0cfeb49e21593385903c79de439a70780a4a827e0df3c215e28634e4